Workflow
血糖检测
icon
Search documents
三诺生物(300298):公司动态研究报告:业绩符合预期,CGM海外拓展持续推进
Huaxin Securities· 2025-09-28 08:59
Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company's performance met expectations, with a revenue of 2.264 billion yuan in the first half of 2025, representing a year-on-year growth of 6.12%. However, the net profit attributable to the parent company was 181 million yuan, a decline of 8.52% year-on-year [4] - The company holds over 50% of the retail market for blood glucose meters in China and ranks as the fourth largest blood glucose meter company globally, with products available in over 3,800 hospitals and more than 400,000 pharmacies [4] - The Continuous Glucose Monitoring (CGM) system remains a key revenue contributor, accounting for over 73% of the company's performance, with ongoing international expansion and product registrations in multiple countries [5] - The company has established a professional health management team and a comprehensive service network covering 187 countries, enhancing its global business development [6] - Revenue forecasts for 2025-2027 are projected at 4.887 billion, 5.572 billion, and 6.129 billion yuan, with corresponding EPS of 0.71, 0.94, and 1.15 yuan, indicating a positive outlook for the company's growth [7] Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 2.264 billion yuan, a 6.12% increase year-on-year, while the net profit decreased by 8.52% to 181 million yuan [4] Market Position - The company commands over 50% of the blood glucose meter retail market in China and is the fourth largest globally, with a user base exceeding 25 million across 187 countries [4] Product Development - The CGM system is the primary revenue source, with over 73% contribution, and the company is expanding its product registration in various international markets [5] Global Strategy - The company has built a robust health management team and service network, facilitating its global business expansion [6] Earnings Forecast - Projected revenues for 2025-2027 are 4.887 billion, 5.572 billion, and 6.129 billion yuan, with EPS estimates of 0.71, 0.94, and 1.15 yuan, reflecting a strong growth trajectory [7]